Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Frametact
Deal Size : $60.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Frametact will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases, such as Alzheimer's, Parkinson's, and Huntington's disease...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Frametact
Deal Size : $60.0 million
Deal Type : Licensing Agreement
Lead Product(s) : AAV-based gene therapy
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration combines Boehringer Ingelheim's experience in disease biology and gene therapy development with CureGenetics' AAV-based gene therapy expertise in library construction and highly efficient in vivo AAV screening with CureGenetics' proprie...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 18, 2021
Lead Product(s) : AAV-based gene therapy
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Discovery Platform
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?